In a recent turn of events, Bridge Biotherapeutics, a South Korea based pharmaceutical company partnered with Germany’s Boehringer Ingelheim in a USD 1.75 billion deal. For Boehringer Ingelheim, it is the second-largest deal having to do with Fibrotic diseases in the same month.
The way the partnership will work is that Boehringer Ingelheim will give Bridge Biotherapeutics a based amount of USD 50.6 million. This will be followed by further milestones payments that are expected to amount up to USD 1.25 billion in total. For any other products that might follow, Bridge Biotherapeutics will also be eligible for any royalties that may be raised in the market. Keep reading to find out everything there is to know about the deal so far.
1. The Product In Question
The drug in question is the BB-877, patented originally by LegoChem Biosciences. It was then licensed over to Bridge Biotherapeutics back in 2017. It is currently in its initial stages of development in the United States, i.e., clinical trials. The main purpose of developing this compound is to combat fibrotic diseases.
These include the likes of Idiopathic Pulmonary Fibrosis or IPF, and non-alcoholic Steatohepatitis or NASH. For starters, however, the main focus of the compound will be towards IPF. The CEO of Bridge Biotherapeutics has expressed appreciation over this new partnership with Boehringer Ingelheim. Considering that the Germany-based company is one of the leading players in the fight against IPF, there are many positive developments to look forward.
2. How Is It Going To Be Used
Since BB-877 is so closely linked to combating IPF, it is only fair to try and define IPF in the first place. Simply put, it causes fibrosis (or scarring) of lung tissues. This results in difficulty in breathing. There are multiple factors that can contribute to the onset of IPF. Some of the more notables ones, including habits such as substance abuse, smoking, etc.
Genetics play a role as well, as does gender. IPF is inherently more common in males as compared to females. Lastly, there is the age plays a role as well with individuals over the age of 50 being more prone to developing IPF. Another area of concern for Boehringer Ingelheim is the fibrotic disease, NASH. That is the cirrhosis of the liver in patients who consume little to no alcohol.
3. Future Projections
Fibrotic diseases are a growing concern in the medical world. However, Boehringer Ingelheim is dedicated to combating these diseases and coming out the other side. These recent collaborations will efficiently pair Boehringer’s resources and advanced technology with the original patent to develop a compound that will hopefully be an answer for long-suffering patients.
Boehringer Ingelheim is already on the right track when it comes to developing a mechanism against growing concerns regarding IPF and NASH. These two deals for fibrotic diseases are a step in the right directions. The parties involved are confident and expect positive results very shortly!